Cancer device in trials

By
Tuesday, 09 October, 2001

A screening device for cervical cancer and pre-cancer, developed by Australian company Polartechnics in collaboration with CSIRO, has entered final clinical trials for regulatory approval for use in Europe.

Over half a million women worldwide are affected by cervical cancer every year and Polartechnics' system has the potential of reducing mortality rates through higher accuracy and instant diagnosis. Trials conducted last year demonstrated it is significantly more accurate than the Pap smear. These tests were done using an interim product and a subset of the female population, those who had already returned a positive Pap smear.

The present trials are being done on the commercial product and are designed to be representative of the entire female population at risk of cervical cancer. The system uses a pen-like probe to collect information directly from the cervix about the colour and electrical properties of cervical tissue. A single-use sensor, which is a plastic sheath that fits over the probe and is used only once, ensures that the process is safe and hygienic.

A computer attached to the probe analyses the data and classifies the tissue as healthy, pre-cancerous or cancerous.

Related News

AXT to distribute NT-MDT atomic force microscopes

Scientific equipment supplier AXT has announced a partnership with atomic force microscope (AFM)...

Epigenetic patterns differentiate triple-negative breast cancers

Australian researchers have identified a new method that could help tell the difference between...

Combined effect of pollutants studied in the Arctic

Researchers from the Fram Centre in Norway are conducting studies in Arctic waters to determine...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd